In:
Journal of Medical Imaging and Radiation Oncology, Wiley, Vol. 58, No. 4 ( 2014-08), p. 472-480
Abstract:
To evaluate the uptake of the liver‐specific magnetic resonance imaging ( MRI ) contrast agent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid ( Gd‐EOB‐DTPA ) by functional liver parenchyma after radioembolisation ( RE ) of hepatic malignancies. Methods Uptake of Gd‐EOB‐DTPA prior to RE versus 60+/−24d and 126+/−32d after RE was compared in a group of 33 patients with primary or secondary hepatic malignancies. In patients who underwent single‐lobe treatment, left and right lobes were compared 59+/−24 days after RE . Gd‐EOB‐DTPA uptake was determined as follows: ratio of mean signal intensity in liver parenchyma to muscle in Gd‐EOB‐DTPA ‐enhanced T 1‐weighted MRI was subtracted from ratio of mean intensity in liver parenchyma to muscle in unenhanced T 1‐weighted MRI . Results Gd‐EOB‐DTPA uptake in liver parenchyma was 0.845+/−0.29 before RE , 0.615+/−0.38 ( P = 0.0022) at day 60+/−24, and 0.739+/−0.30 at day 126+/−32 after RE . In cases of single‐lobe treatment, Gd‐EOB‐DTPA uptake was 0.581+/−0.256 for treated and 0.828+/−0.32 ( P = 0.0164) for untreated hepatic lobes. Conclusions Uptake of Gd‐EOB‐DTPA by liver parenchyma is impaired after RE , indicating dysfunction of the local hepatic system. These findings suggest that Gd‐EOB‐DTPA ‐enhanced MRI has the potential to be used for monitoring liver damage after RE .
Type of Medium:
Online Resource
ISSN:
1754-9477
,
1754-9485
DOI:
10.1111/jmiro.2014.58.issue-4
DOI:
10.1111/1754-9485.12187
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2409071-2
Permalink